Why Geron Stock Crept Higher Today
Shares of commercial-stage biotech (NASDAQ: GERN) couldn't quite surmount the hump of Hump Day. After the company released its latest set of quarterly figures, its stock price wobbled as investors determined how best to digest the results. Finally, the stock closed on a downbeat note, booking a 0.8% loss on the day and comparing unfavorably to the slight (0.4%) gain of the S 500 index.
Geron unveiled its first-quarter numbers well before market open, showing that the oncology-focused biotech earned $39.6 million during the period. Nearly all of this was derived from sales of Rytelo, the company's cancer drug that won Food and Drug Administration (FDA) approval in June 2024. Year-over-year comparisons are therefore meaningless, as the company had no product revenue in the first quarter of 2024.
Image source: Getty Images.
Source Fool.com
Geron Corp. Aktie
Die Geron Corp. Aktie ist etwas beliebter: Mehr Buy- (3) als Sell-Einschätzungen (1).
Für Geron Corp. ergibt sich mit einem Kursziel von 2 € eine mögliche Steigerung von über 20% gegenüber 1.43 €.
